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The Open University’s first one day symposium on treatment-emergent neuroendocrine prostate 
cancer attracted world-leading figures, early career researchers, and industry colleagues. The 
symposium proved insightful into the ‘real-world’ impact and current problems faced in the 
diagnosis and treatment of neuroendocrine prostate cancer. It was important for this meeting to 
take place as the incidence of NEPC is increasing due to the widespread use of next-generation 
androgen depravation drugs. 
The symposium discussions proposed new molecularly-driven deadlines to accelerate research and 
improved the treatment of this deadly and poorly recognised malignancy. 
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Introduction 
Treatment-emergent neuroendocrine prostate cancer (NEPC) is a recently identified clinico-
pathological subtype of prostatic neoplasm, which is characterised by dismal prognosis and 
complete resistance to any hormonal therapy [1]. The Open University’s hosted its first one day 
symposium entitled ‘Treatment-emergent neuroendocrine prostate cancer’ on 25th June 2019. The 
symposium attracted 39 clinicians, researchers and students from across the UK and internationally, 
who gathered to share, hear and debate the very latest developments in neuroendocrine prostate 
cancer research.  
The programme featured keynotes from world-leading figures, early career researchers, and 
industry colleagues, proving impactful insights and current problems faced in the diagnosis and 
treatment of NEPC. A broad range of topics were covered including clinical diagnosis, molecular 
mechanisms of disease progression, and the development of novel biomarkers and therapeutics.  
Highlights 
Highlights of the first session included an insight into the clinical progression of prostate cancer. 
Professor Hardev Pandha, director of the Surrey Cancer Centre (Surrey UK), described the clinical 
presentation of prostate cancer and his experience managing neuroendocrine disease. Prof Pandha 
highlighted difficulties associated with diagnosing this complex pathology, and also the problems 
associated with second-line anti-androgens (abiraterone, enzalutamide). The lecture concluded by 
recommending re-biopsy of patients with suspected NEPC in order to improve accurate diagnosis 
(i.e. not waiting for treatment failure) and in doing so also treating patients more specifically and 
also increasing research material for better understanding this disease.  
Following Professor Pandha’s presentation,  Dr Francesco Crea, Senior Lecturer at The Open 
University (Milton Keynes UK), discussed the cellular origins of prostate cancer and the ‘classical’ 
model of NEPC development [2]. Classically NEPC was thought to arise from oncogenic 
transformation of basal cells, distinct from the oncogenic transformation of luminal cells which give 
rise to prostatic adenocarcinoma [3]. However this model has been challenged by several studies 
[4,5]. These studies provide evidence that prostatic adenocarcinomas treated with second-line anti-
androgens may give rise to either CRPC, or NEPC through a largely mechanistically unknown trans-
differentiation process. Both Prof. Pandha and Dr Crea stated that the incidence of NEPC is likely to 
rise with increased use of second line anti-androgens, and recommended re-biopsying patients with 
suspected NEPC after therapy.  
To conclude the morning’s clinical session, a discussion including Dr Jake Micallef from 
biotechnology company Volition (Isnes Belgium), Prof. Pandha, Dr Crea, and Mr Henry Andrews, a 
urologist from Milton Keynes Hospital then took place. The panel briefly introduced themselves and 
the audience then insightfully and openly discussed with the panel how the NEPC community can 
work together to change current guidelines. This change in guidelines is necessary to improve not 
only rapid diagnosis, but unnecessary use of ineffective treatments. It is only then we can begin to 
identify effective treatments against this disease. To underscore the importance of new guidelines, 
Dr Pandha presented 2 clinical cases in both cases biopsies were taken from CRPC patients that had 
shown progression after abiraterone or enzalutamide treatment. In both cases, the hormonal 
therapy was substituted by platinum-based chemotherapy. Dr Pandha stated that since June 2018 
his Cancer Centre had identified and treated 7 NEPC patients, identified by soft tissue biopsies. For 
the Surrey NEPC project Prof. Pandha indicated that they would radiologically monitor 100 CRPC 
patients and biopsy when clinically indicated, as well as work to develop serum markers in order to 
improve diagnosis.  
In the afternoon session, the molecular mechanisms of NEPC initiation and progression were 
discussed. Prof Yuzhuo Wang from the BC Cancer Agency (Vancouver Canada) gave a lecture on his 
lab’s approach to the challenge of targeting NEPC using a pipeline ranging from discovery to drug 
development. Prof. Wang first described the expression and function of HP1a knock-down in various 
NEPC models demonstrating that this protein regulates NEPC cell survival and growth [6]. Prof Wang 
further described that HP1a also induces the neuroendocrine phenotype in prostatic 
adenocarcinoma cells upon over-expression. Mechanistically Prof Wang then described that HP1a 
works by enriching histone 3 lysine trimethylation (H3Kme3) on AR and REST promoters which 
represses their expression, promoting the NEPC phenotype. Concluding this data Prof Wang 
suggested HP1a as a serum marker, and as a druggable target to prevent trans-differentiation to 
NEPC, and for NEPC.  Prof. Wang then described another target identified by his lab after going back 
to one of the fundamental hallmarks of cancer, evasion of the immune response. MCT4, a 
transporter protein, was identified in prostate cancer as a possible immune regulator [7]. This 
protein is a transporter involved in glycolytic phenotypes. By designing anti-sense oligonucleotides 
against this protein, the study demonstrated enhanced anti-cancer immunity in PC-3 bearing nude 
mice and in a first generation PDX mode [8]l. This model demonstrated increased tumour-associated 
NK cells after anti-sense treatments (PC-3), and in proliferation of patient tumour-associated CD8+ T-
cells indicating that this transporter regulates the immune response.   
In the following talk, Dr Rebecca Mather, a post-doctoral research associate at The Open University, 
then spoke about the long non-coding RNA landscape of NEPC [9,10]. This was approached from a 
screen of long non-coding RNAs in PDX models and clinical samples using databases prioritising 
dysregulated transcripts which were evolutionary conserved and up-regulated in NEPC. One of these 
transcripts NEAR1 was functionally characterised using genetic techniques and was shown to 
regulate cell proliferation, survival and invasion. Mechanistically NEAR1 was shown to act by driving 
transcription of the pioneer transcription factor, and proposed NEPC biomarker, FOXA2. Next 
generation anti-sense oligonucleotides are also being developed against this transcript as a possible 
therapy, and this transcript also shows promise as a urinary biomarker.  
Finally, Dr Elena Jachetti, researcher at The Istituto Nazionale dei Tumori (Milan Italy) gave a lecture 
on stromal accomplices driving neuroendocrine features in prostate cancer. Using the TRAMP mouse 
models of prostate cancer Dr Jachetti focused on the mast cell component of the tumours, showing 
that well-differentiated prostate adenocarcinomas need mast cells for in vivo tumour growth by 
provision of the matrix metalloprotease MMP9. Dr Jachetti then blocked mast cell degranulation 
(and therefore MMP9) in these models and found that despite the effect on adenocarcinoma 
growth, NEPC arose in these mice with greater incidence. Osteopontin was also discussed as another 
mediator released by mast cells. Indeed, Dr Jachetti showed that TRAMP mice knock-outs of 
osteopontin also had increased NEPC incidence. When Dr Jachetti then injected mast cells into these 
mice, the mast cells which were wild-type for osteopontin, but not osteopontin knock-out, reduced 
the frequency of NEPC tumours, indicating that osteopontin from mast cell was essential for this 
process [11,12].  
Conclusion 
In conclusion, the symposium has been a unique occasion to gather scientists and clinicians working 
on treatment-emergent NEPC, and to propose new molecularly-driven deadlines to accelerate 
research and improved the treatment of this deadly and poorly recognised malignancy. Key findings 
from this symposium are new guidelines for the prompt diagnosis and management of treatment-
emergent NEPC, as well as molecular evidence indicating the importance of epigenetic factors, non-




1. Aggarwal R, Huang J, Alumkal JJ et al. Clinical and Genomic Characterization of Treatment-
Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective 
Study. J. Clin. Oncol. 36(24), 2492–2503 (2018). 
2. Crea F. Neuroendocrine prostate cancer: long noncoding RNAs to treat an incurable cancer - 
an interview with Dr Francesco Crea. Epigenomics 11(13), 1461–1462 (2019). 
3. Crea F, Venalainen E, Ci X et al. The role of epigenetics and long noncoding RNA MIAT in 
neuroendocrine prostate cancer. Epigenomics 8(5), 721–731 (2016). 
4. Beltran H, Prandi D, Mosquera JM et al. Divergent clonal evolution of castration-resistant 
neuroendocrine prostate cancer. Nat. Med. 22(3), 298–305 (2016). 
5. Lin D, Wyatt AW, Xue H et al. High fidelity patient-derived xenografts for accelerating 
prostate cancer discovery and drug development. Cancer Res. 74(4), 1272–1283 (2014). 
6. Ci X, Hao J, Dong X et al. Heterochromatin Protein 1α Mediates Development and 
Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Res. 78(10), 2691–2704 (2018). 
7. Choi SY, Xue H, Wu R et al. The MCT4 Gene: A Novel, Potential Target for Therapy of 
Advanced Prostate Cancer. Clin. Cancer Res. 22(11), 2721–2733 (2016). 
8. Choi SYC, Ettinger SL, Lin D et al. Targeting MCT4 to reduce lactic acid secretion and 
glycolysis for treatment of neuroendocrine prostate cancer. Cancer Med.  (2018). 
9. Crea F, Clermont PL, Parolia A, Wang Y, Helgason CD. The non-coding transcriptome as a 
dynamic regulator of cancer metastasis. Cancer Metastasis Rev. 33(1), 1–16 (2014). 
10. Mather RL, Wang Y, Crea F. Is HOTAIR really involved in neuroendocrine prostate cancer 
differentiation? Epigenomics 10(10), 1259–1261 (2018). 
11. Mauri G, Jachetti E, Comuzzi B et al. Genetic deletion of osteopontin in TRAMP mice skews 
prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine 
cancers. Oncotarget 7(4), 3905–3920 (2016). 
12. Pittoni P, Tripodo C, Piconese S et al. Mast cell targeting hampers prostate adenocarcinoma 
development but promotes the occurrence of highly malignant neuroendocrine cancers. 
Cancer research 71(18), 5987–5997 (2011). 
 
